Objectives To describe the global trends of pulmonary nontuberculous mycobacteria (NTM)
infection and disease. Methods A systematic review of studies including culture-based NTM …

Tuberculosis (TB) drug discovery and development has undergone nothing short of a
revolution over the past 20 years. Successful public–private partnerships and sustained …

Talaromycosis is an invasive mycosis endemic in tropical and subtropical Asia and is
caused by the pathogenic fungus Talaromyces marneffei. Approximately 17,300 cases of T …

Inhaled corticosteroids (ICS) combined with bronchodilators can reduce the frequency of
exacerbations in some patients with chronic obstructive pulmonary disease (COPD). There …

BACKGROUND Non-tuberculous pulmonary disease (NTM-PD) is widely underdiagnosed
and certain patient groups, such as those with underlying respiratory diseases, are at …

Tuberculosis (TB), the world's deadliest bacterial infection, afflicts more human males than
females, with a male/female (M/F) ratio of 1.7. Sex disparities in TB prevalence …

Background Shotgun metagenomic next-generation sequencing (mNGS) is widely used to
detect pathogens in bronchoalveolar lavage fluid (BALF). However, mNGS is complex and …

ABSTRACT SPR720 (phosphate prodrug of SPR719) is a novel aminobenzimidazole
bacterial DNA gyrase (GyrB) inhibitor in development for nontuberculous mycobacterial …

Introduction Nontuberculous mycobacterial (NTM) lung disease (LD) is the most common
clinical manifestation of NTM infection and is a growing health concern. Up to 85% of NTM …

Bronchiectasis and nontuberculous mycobacteria (NTM) are intricately intertwined, with
NTM capable of being both a cause and consequence of bronchiectatic disease. This …